Innovation is in our industry’s DNA. It’s the vehicle by which we improve patients’ lives, evolve the way we manage healthcare and benefit wider society.
The Academy of Medical Royal Colleges, which includes the Faculty of Pharmaceutical Medicine, recognises the need for increased transparency in relation to Conflicts of Interest in medicine and healthcare. By declaring any conflicts publicly, the Academy has long argued that transparency will be...
Each year we support a different charity in the run up to Christmas. This year we have chosen Crisis, the national charity for homeless people.
The 2017 Queen's Speech took place today [21 June] at the State Opening of Parliament. With the Government having announced that there will be no Queen's Speech in 2018, this Queen's Speech sets out the Government's legislative agenda for the next two years.
The Government has published the level of payment due from members of the Pharmaceutical Price Regulation Scheme (PPRS) in 2017 to keep health service spend on branded medicines within the levels agreed under the Scheme.
The UK pharmaceutical industry trade body, the Association of the British Pharmaceutical Industry (ABPI), have responded to the Prime Minister's speech on the Government's negotiating objectives for exiting the EU.
When you google clinical trials today it brings up images of clinical settings, white coats and test tubes. But the first clinical trial was a very different experience.
Today we published our response to the GMC consultation on 'Good practice in prescribing and managing medicines and devices'.
In the second of a series of blogs in the run up to the ABPI annual conference –‘Securing a future for innovative medicines’ – Alison Clough, Commercial Director of the ABPI, looks at how the commercial environment needs to work with the evolving research and development (R&D) ecosystem.
In the last couple of weeks we’ve seen a number of articles in the press describing the Cancer Drugs Fund a ‘tragedy for patients’ and a ‘waste of money’.